Importance of magnesium depletion with hypofunction of the biological clock in the pathophysiology of headhaches with photophobia, sudden infant death and some clinical forms of multiple sclerosis

Magnesium Research

Volumn 17, Issue 4, 2004, Pages 314-326

  Durlach, J ^a,d   Pages N ^b   Bac, P ^c   Bara, M ^a   Guiet Bara, A ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b Faculte de Pharmacie   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SDRM   (France)

Author keywords

Anxiety; Chronobiology; Headache; Magnesium; Migraine; Multiple sclerosis; Sudden infant death

Indexed keywords

ADIPOSE TISSUE; ANXIETY; ARTICLE; BIOLOGICAL RHYTHM; BRAIN DEPTH STIMULATION; CHRONOBIOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORRELATION ANALYSIS; DARK ADAPTATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; FREQUENCY ANALYSIS; HEADACHE; HOMEOSTASIS; HUMAN; LATITUDE; MAGNESIUM DEPLETION; MIGRAINE; MORBIDITY; MULTIPLE SCLEROSIS; NEUROMODULATION; OCCIPITAL CORTEX; PATHOPHYSIOLOGY; PHOTOPHOBIA; PHOTOSENSITIVITY; SUDDEN INFANT DEATH SYNDROME; SUMMER; WEATHER;

BIOLOGICAL CLOCKS; HEADACHE; HUMANS; INFANT; INFANT, NEWBORN; MAGNESIUM; MULTIPLE SCLEROSIS; PHOTOPHOBIA; SUDDEN INFANT DEATH;

EID: 12844249500     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A. Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of Mg depletion. Magnes Res 2002; 15: 49-66.
2. Durlach J. Editorial Policy of Magnesium Research: General considerations on the quality criteria for biomedical papers and some complementary guidelines for the contributors of Magnesium Research. Magnes Res 1995; 8: 191-206.
3. Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A, Agrapart C. Chronopathological forms of magnesium depletion with hypofunction or with hyperfunction of the biological clock. Magnes Res 2002; 15: 263-8.
4. Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A. Magnesium deficit and sudden infant death syndrome (SIDS): SIDS due to magnesium deficiency and SIDS due to various forms of magnesium depletion: possible importance of the chronopathological form. Magnes Res 2002; 15: 269-78.
5. Main A, Vlakonikolig I, Dowson A. The wavelength of light causing photophobia in migraine and tension-type headache between attacks. Headache 2000; 40: 194-9.
6. Keller M, Wiedemann Z, Zihl J. Illumination perception in photophobic patients suffering from panic disorder with agoraphobia. Acta Psychiatr Scand 1997; 96: 72-4.
7. Salvesen R, Bakkelund SI. Migraine as compared to other headaches is worse during midnight-sun summer than during polar night. A questionnaire study in an Arctic population. Headache 2000; 40: 824-9.
8. Fox AW, Davis RL. Migraine chronobiology. Headache 1998; 38: 436-41.
9. Goto Y, Furuta A, Tobimatsu S. Magnesium deficiency differentially affects the retina and visual cortex of intact rats. J Nutr 2001; 131: 2378-81.
10. Mulleners WM, Chronicle EP, Vredeveld JW, Koehler PJ. Visual cortex excitability before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol 2002; 9: 35-40.
11. Claustrat B, Brun J, Borson-Chazot F. Mélatonine et rythmes circadiens. Rev Neurol 2001; 157(5S): 121.
12. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia: a preliminary study. Arch Gerontol Geriatr 2000; 31: 65-76.
13. Parain D. Les épilepsies photosensibles géné ralisées ou focales. Rev Neurol 1998; 154: 757-61.
14. Salas-Puig J, Parra J, Fernandez-Torre JL. Photogenic epilepsy. Rev Neurol 2000; 30: S81-S84.
15. Harding GFA. TV can be bad for your health. Nat Med 1998; 4: 265-7.
16. Panayotopoulos CP. Fixation-off, scotosensitive and other visual-related epilepsies. In: Zifkin BG, et al., eds. Reflex epilepsies and reflex seizures: Advances in neurology, Vol. 75. Philadelphia: Lippincott-Raven, 1998: 139-57.
17. Durlach J. Chronic fatigue syndrome and chronic primary magnesium deficiency. Magnes Res 1992; 5: 68.
18. Sandrini G, Proietti Cecchini A, Nappi G. Chronic fatigue syndrome: a borderline disorder. Funct Neurol 2002; 17: 51-2; (abstract).
19. Wikner J, Hirsh U, Nettenberg L, Röjdmark S. Fibromyalgia: a syndrome associated with decreased nocturnal MT secretion. Clin Endocrinol (Oxf) 1998; 49: 179-83.
20. Vivayan N, Gould S, Watson C. Exposure to sun and precipitation of migraine. Headache 1980; 20: 42-3.
21. Blau JN. Migraine pathogenesis: the neural hypothesis reexamined. J Neurol Neurosurg Psychiatry 1984; 47: 437-42.
22. Drummond PD. A quantitative assessment of photophobia in migraine and tension headache. Headache 1986; 26: 465-9.
23. Woodhouse A, Drummond PD. Mechanisms of increased sensitivity to noise and light in migraine headache. Cephalalgia 1993; 13: 417-20.
24. Main A, Dawson A, Gross M. Photophobia and phonophobia in migraineurs betwen attacks. Headache 1997; 37: 492-5.
25. Vingen JV, Sand T, Stovner LJ. Sensitivity to various stimuli in primary headaches: a questionnaire study. Headache 1999; 3: 552-8.
26. Rossi LN, Cortinovis I, Menegazzo L, Brunelli G, Bossi A, Macchi M. Classification criteria and distinction between migraine and tension headache in children. Dev Med Child Neurol 2001; 43: 45-51.
27. Durlach J, Bac P, Durlach V, Bara M, Guiet-Bara A. Neurotic, neuromuscular and autonomic nervous form of magnesium imbalance. Magnes Res 1997; 10: 169-95.
28. Durlach J, Bara M. In: Le Magnésium en biologie et en médecine. France: EMinter ed., publ. Cachan, 2000: 98-9.
29. Durlach J, Bac P, Bara M, Guiet-Bara A. Physiopathology of symptomatic and latent forms of central nervous hyperexcitability due to magnesium deficiency: a current general scheme. Magnes Res 2000; 13: 293-302.
30. Ramadan NM, Halvorson H, Vandelinde A, Levine S, Helpern JA, Welsh KMA. Low brain magnesium in migraine. Headache 1989; 29: 590-3.
31. Schoenen J, Sianard-Gainko J, Lenaerts M. Blood magnesium levels in migraine. Cephalalgia 1991; 11: 97-9.
32. Thomas J, Thomas E, Tomb E. Serum and erythrocyte magnesium concentrations and migraine. Magnes Res 1992; 5: 127-30.
33. Gallai V, Sarchielli P, Costa G, Firenze C, Mozucci P, Abbritti G. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients. Cephalalgia 1992; 32: 132-5.
34. Castelli S, Meossi C, Domenici R, Fontana F, Stefani G. Il magnesio nella profilassi della cefaleo primaria e di altri disturbi periodici del bambino. Ped Med Chir(Med Surg Ped) 1993; 15: 481-8.
35. Mauskop A, Altura BT, Cracco RQ, Altura BM. Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Headache 1993; 33: 135-8.
36. Gallai V, Sarchielli P, Mozucci P, Abbritti G. Red blood cell magnesium levels in migraine patients. Cephalalgia 1993; 13: 74-81.
37. Soriani S, Arnaldi C, de Carlo L, Arcudi D, Mazzotta D, Battistella PA, Sartori S, Abbasciano V. Serum and red blood cell magnesium levels in juvenile migraine patients. Headache 1995; 35: 14-6.
38. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Gobel H, Fisher H. Magnesium in the prophylaxis of migraine: a double blind placebo-controlled study. Cephalalgia 1996; 16: 346.
39. Aloisi P, Marreli A, Porto C, Tozzi F, Cerone G. Visual evoked potentials and serum magnesium levels in juvenile migraine patients. Headache 1997; 37: 383-5.
40. Mishima K, Takeshima T, Shimomura T, Okada H, Kitano A, Takahashi K, Nakashima K. Platelet ionized magnesium, cyclic AMP and cyclic GMP levels in migraine and tension-type headache. Headache 1997; 37: 561-4.
41. Lodi R, Iotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, Soriani S, Montagna P, Barbiroli B. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001; 54: 437-41.
42. Teppert JJ, Rapoport AM, Sheftell FD. The pathophysiology of migraine. Neurology 2001; 7: 279-86.
43. Boska MD, Welch KM, Barker PB, Nelson JA, Schultz L. Contrast in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Headache 2002; 42: 114-9.
44. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. New migraine preventive options: an update with pathophysiological considerations. Rev Hosp Clin Fac Med Sao Paulo 2002; 57: 293-8.
45. Thompson RF, Spencer WA. Habituation: a model phenomenon for the study of neuronal substrates behaviour. Psychol Rev 1966; 73: 16-43.
46. Monnier M, Boehmer A, Scholer A. Early habituation, dishabituation and generalization induced in the visual centres by colour stimuli. Vision Res 1976; 16: 1497-504.
47. Schoenen J. Clinical neurophysiology studies in headache: a review of data and pathophysiological hints. Funct Neurol 1992; 7: 191-204.
48. Schoenen J. Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behaviour and trigeminovascular activation? Biomed Pharmacother 1996; 50: 71-8.
49. Wang W, Wang GP, Ding XL, Wang YH. Personality and response to repeated visual stimulation in migraine and tension type headache. Cephalalgia 1999; 19: 719-24.
50. Ambrosini A, Schoenen J. The electrophysiology of migraine. Curr Opin Neurol 2003; 16: 327-31.
51. Marcus DA. Migraine and tension type headaches: the questionable validity of the current classification system. Clin J Pain 1992; 8: 28-36.
52. Farkila M. The pathophysiology of migraine. Ann Med 1994; 26: 7-8.
53. Spierings ELH. In: Migraine. Questions and answers. Merit Publ. Internat., 1995: 54-5.
54. De Tommaso M, Sciruicchio V, Guido M, Sasanelli G, Puca F. Steady state visual-evoked potentials in headache: diagnostic value in migraine and tension type headache patients. Cephalalgia 1999; 19: 23-6.
55. Evers S, Quibeldey F, Grotemeyer KH, Suhr B, Husstedt IW. Dynamic changes of cognitive habituation and serotonin metabolism during the migraine interval. Cephalalgia 1999; 19: 485-91.
56. Van Dijk JG. Neurophysiological evidence of increased cortical reactivity in migraine. Funct Neurol 2000; 15(Suppt.to no3): 73-7.
57. Sand T, Vanagaite Vingen J. Visual long-latency auditory and brainstem auditory evoked potentials in migraine: relation to pattern size, stimulus intensity, sound and light discomfort thresholds and pre-attack state. Cephalalgia 2000; 20: 804-20.
58. Sheperd AJ. Visual contrast processing in migraine. Cephalalgia 2000; 20: 865-80.
59. Bowyer SM, Aurora SK, Moran JE, Tepley N, Welch KMA. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001; 50: 582-7.
60. Welch KMA, Bowyer SM, Aurora SK, Moran JE, Tepley N. Visual-stress induced migraine compared to spontaneous aura studied by magnetoencephalography. J Headache Pain 2001; 2: S131-S136.
61. Sheperd AJ. Increased visual after-effects following pattern adaptation in migraine: a lack of intra-cortical excitation. Brain 2001; 124: 2310-8.
62. Bäcker M, Sander D, Hammes MG, Funk D, Deppe M, Conrad B, Trolle TR. Altered cerebrovascular pattern in interictal migraine during visual stimulation. Cephalalgia 2001; 21: 611-6.
63. Legrain V, Janne P, Laloux P, Ossemann M, Dupuis M, Regnaert C. Intérêts cliniques et physiopathologiques des potentiels évoqués cognitifs dans la migraine (Clinical and pathophysiological contribution of event-related potentials used to study migraine headache). Rev Neurol (Paris) 2001; 157: 365-75.
64. Shepperd AJ, Palmer JE, Davis G. Increased visual after-effects in migraine following pattern adaptation extend to stimultaneous tilt illusion. Spat Vis 2002; 16: 33-4.
65. De Marinis M, Pujia A, Natale L. D'arcangelo E, Accornero N. Decreased habituation of the R2 component of the blink reflex in migraine patients. Clin Neurophysiol 2003; 114: 889-93.
66. Friberg L, Sandrini G, Jänig W, Jensen R, Russel D, Sanchez del Rio M, Sand T, Schoenen J, Van Buchem M, Van Dijk JG. Instrumental investigations in primary headache. An updated review and new prospectives. Funct Neurol 2003; 18: 127-44.
67. Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A. New data on the importance of gestational magnesium deficiency. Magnes Res 2004; 17: 116-25.
68. Heipertz R, Eickhoff K, Karstens KH. Magnesium and inorganic phosphate content in CSF related to blood brain barrier function in neurological disease. J Neurol Sci 1979; 40: 87-95.
69. Moscarello MA, Chia LS, Leighton D, Absolom D. Size and surface charge properties of myelin vesicles from normal and diseased (Multiple Sclerosis) brain. Neurochem 1985; 45: 415-21.
70. Hasanen E, Kinnunen E, Alhonen P. Relationship between the prevalence of Multiple Sclerosis and some physical and chemical properties of soil. Sci Total Environ 1986; 58: 263-72.
71. Yasui M, Yase Y, Ando K, Adachi K, Mukoyama M, Ohsugi K. Magnesium concentration in brains from Multiple Sclerosis patients. Acta Neurol Scand 1990; 81: 187-200.
72. Yasui M, Ota K. Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of Multiple Sclerosis. Magnes Res 1992; 5: 295-302.
73. 2+. Scand J Clin Lab Invest Suppl 1994; 217: 77-81.
74. Slelmasiak Z, Solski J, Jakubowska B. Magnesium concentration in plasma and erythrocytes in Multiple Sclerosis. Acta Neurol Scand 1995; 92: 109-11.
75. Durlach J, Bac P, Durlach V, Bara M, Guiet-Bara A. Are age-related neurodegenerative diseases linked with various types of magnesium depletion? Magnes Res 1997; 10: 339-53.
76. Johnson S. The possible role of gradual accumulation of Cu, Cd, Pb and Fe and gradual depletion of Zn, Mg, Se, vitamins B2, B6, D and E and essential fatty acids in Multiple Sclerosis. Med Hypotheses 2000; 55: 239-41.
77. Bolviken B, Celius EG, Nilsen R, Strand T. Radon: a possible risk factor in Multiple Sclerosis. Neuroepidemiology 2003; 22: 87-94.
78. Davenport CB. Multiple Sclerosis from the standpoint of geographic distribution and race. Arch Neurol Psychiatry 1922; 8: 51-60.
79. Norman JE, Kurtzke JF, Beebe GW. Epidemiology of Multiple Sclerosis in US veterans: 2. Latitude, climate and the risk of Multiple Sclerosis. J Chronic Dis 1983; 36: 551-9.
80. Rosen LN, Livingstone IR, Rosenthal NE. Multiple Sclerosis and latitude: a new perspective and an old association. Med Hypotheses 1991; 36: 376-8.
81. Hutter CDD, Laing P. Multiple Sclerosis: Sunlight, diet, immunology and aetiology. Med Hypotheses 1996; 46: 67-74.
82. Carlyle IP. Multiple Sclerosis: a geographical hypothesis. Med Hypotheses 1997; 49: 477-86.
83. Compston DA, Batchelor JR, Earl CJ, McDonald WI. Factors influencing the risk of Multiple Sclerosis developing in patients with optic neuritis. Brain 1978; 101: 495-511.
84. Contantinescu CS, Hilliard B, Ventura E. Luzindole, a melatonin receptor antagonist, suppresses experimental antoimmune encephalomyelitis. Pathobiology 1997; 65: 190-4.
85. Maestroni GJM. The immunotherapeutic potential of melatonin. Exp Opin Invest Drugs 2001; 10: 466-7.
86. Constantinescu CS. Melanin, melatonin, MSH and the susceptibility to antoimmune demyelinisation: a rationale to light therapy in Multiple Sclerosis. Med Hypotheses 1995; 45: 455-8.
87. McMichael AJ, Hall AJ. Does immunosuppressive UV radiation explain the latitude gradient for Multiple Sclerosis? Epidemiology 1997; 8: 642-5.
88. Ponsonby AL, McMichael A, Van der Mei I. UV radiation and antoimmune disease: insights from epidemiological research. Toxicology 2002; 181-2: 71-8.
89. Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immune-related disorders including type I diabetes in Australia: latitude regional UV radiation and disease prevalence. Environ Health Perspect 2003; 11: 518-23.
90. Van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T. Past exposure to sun, skin phenotype and risk of Multiple Sclerosis. BMJ 2003; 327: 316.
91. Hayes CE. Vitamin D: a natural inhibitor of Multiple Sclerosis. Proc Nutr Soc 2000; 59: 531-5.
92. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence. Br J Nutr 2003; 89: 552-72.
93. Sandyk R, Awerbuch GI. The pineal gland in multiple sclerosis. Intern J Neurosc 1991; 61: 61-7.
94. Sandyk R, Awerbuch GI. Nocturnal plasma MT and MSH levels during exacerbation of multiple sclerosis. Intern J Neurosc 1992; 67: 173-86.
95. Sandyk R. Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis. Intern J Neurosc 1993; 68: 209-25.
96. Sandyk R. Nocturnal MT secretion in multiple sclerosis patients with affective disorders. Intern J Neurosc 1993; 68: 227-40.
97. Sandyk R, Awerbuch GI. Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. Intern J Neurosc 1993; 71: 147-57.
98. Sandyk R, Awerbuch GI. Relationship of nocturnal MT levels to duration and course of multiple sclerosis. Intern J Neurosc 1994; 75: 229-37.
99. Sandyk R, Awerbuch GI. The relationship of pineal calcification to cerebral atrophy on CT scan in multiple sclerosis. Intern J Neurosc 1994; 76: 71-9.
100. Sandyk R, Awerbuch GI. The cooccurence of multiple sclerosis and migraine headache: the serotoninergic link. Intern J Neurosc 1994; 76: 249-57.
101. Sandyk R. Role of the pineal gland in multiple sclerosis: a hypothesis. J Altern Complement Med 1997; 3: 267-90.
102. Sakai N, Miyajima H, Shimizo T, Arai K. Syndrome of inappropriate secretion of ADH associated with MS. Intern Med 1992; 31: 463-6.
103. Huitinga I, de Groot CJ, Van der Valk P, Kamphorst W, Tilders PJ, Swaab DF. Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol 2001; 60: 1208-18.
104. Huitinga I, Erkurt ZA, Van Beurden D, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004; 55: 37-45.
105. Neutel CI. Multiple sclerosis and the Canadian climate. J Chron Dis 1980; 33: 47-56.
106. Bamford CR, Sibley WA, Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 1983; 33: 697-701.
107. Laborde JM, Dando WA, Teetzen ML. Climate, diffused solar radiation and multiple sclerosis. Soc Sci Med 1988; 27: 231-8.
108. Harbison JW, Calabrese VP, Edlich RF. A fatal case of sun exposure in a multiple sclerosis patient. J Emerg Med 1989; 7: 465-7.
109. O'Reilly MA, O'Reilly PM. Temporal influences on relapses of multiple sclerosis. Eur Neurol 1991; 31: 391-5.
110. Kurtzke JF, Delasnerie-Laupretre N. Reflection on the geographic distribution of multiple sclerosis in France. Acta Neurol Scand 1996; 93: 110-7.
111. Hayes CE, Cantorna MT, de Luca H. Vitamin D and multiple sclerosis. PSEBM 1997; 216: 21-7.
112. Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997; 72: 871-8.
113. Jin Y, de Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H. Seasonal patterns in optic neuritis and multiple sclerosis: a metanalysis. J Neurol Sci 2000; 181: 56-64.
114. Azoulay-Cayla A. La sclérose en plaques est-elle une maladie d'origine virale? (Is multiple sclerosis a disease of viral origin?). Path Biol 2000; 48: 4-14.
115. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117-39.
116. Pugliatti M, Sotgiu S, Solinas G, Gastiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing link. Acta Neurol Scand 2001; 103: 20-6.
117. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Rosati G. Multiple sclerosis prevalence among Sardinians: further evidence against the latitude gradient theory. Neurol Sci 2001; 22: 163-5.
118. Zivadinov R, Iona L, Monti-Bragadin L, Bosco A, Jurjevic A, Tans C, Cazzato G, Zorzon M. The use of the standardized incidence and prevalence rates in the epidemiological studies on multiple sclerosis. Neuroepidemiology 2003; 22: 65-74.
119. Feinstem A. O'Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999; 5: 323-6.
120. Riether AM. Anxiety in patients with multiple sclerosis. Semin Clin Neuropsychiatry 1999; 4: 103-13.
121. Minden SL. Mood disorders in multiple sclerosis: diagnosis and treatment. J Neurovirol 2000; 6: S160-S167.
122. Zorzon M, de Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cassato G, Bratina A, Zivadinov R. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 2001; 248: 416-21.
123. Defer G. Evaluation neuropsychologique et psychopathologique dans la sclérose en plaques (Neurophysiological and psychopathological assessment in multiple sclerosis). Rev Neurol (Paris) 2001; 157: 1128-34.
124. Léger E, Ladouceur R, Freeston MH. Anxiété et limitation physique: une relation complexe (Anxiety and physical limitation: a complex relation). Encephale 2002; 28: 205-9.
125. Rumbach L, Tongio MM, Warter JM, Collard M, Kurtz D. Multiple sclerosis, sleep latencies and HLA antigens. J Neurol 1989; 236: 309-10.
126. Taphoorn MJ, Van Someren E, Snoek FJ, Strijers RL, Swaab DF, Visscher F, de Waal LP, Polman CH. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol 1993; 240: 446-8.
127. Tachibana N, Howard RS, Hirsh NP, Miller DH, Moseley IF, Fish D. Sleep problems in multiple sclerosis. Eur Neurol 1994; 34: 320-3.
128. Ferini-Strambi L, Filippi M, Martinelli V, Oldani A, Rovaris M, Zucconi M, Comi G, Smirne S. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain Magnetic Resonance Imaging findings. J Neurol Sci 1994; 125: 194-7.
129. Aner RN, Rowlands CJ, Perry SF, Reunners JE. Multiple sclerosis with medullary plaques and fatal sleep apnea (Ondine's curse). Clin Neuropathol 1996; 15: 101-5.
130. Poirrier P. Photopériode, photothérapie et troubles du rythme veille-sommeil (Photoperiod, phothotherapy and wakefulness-sleep rhythm disorders). Rev Neurol (Paris) 2001; 157: S140-S144.
131. Iseki K, Mesaki T, Oka Y, Terada K, Torimoto H, Miki Y, Shibasaki H. Hypersomnia in multiple sclerosis. Neurology 2002; 59: 2006-7.
132. Watkins SM, Espir M. Migraine and multiple sclerosis. J Neurol Neurosurg Psychiatry 1969; 32: 35-7.
133. Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. Can J Neurol Sci 1989; 16: 63-6.
134. Buchholtz DW, Reich SG. The menagerie of migraine. Semin Neurol 1996; 16: 83-93.
135. Haufschild T, Shaw SG, Kesselring J, Flammer J. Increased endothelin-I plasma levels in patients with multiple sclerosis. J Neuro-Ophtalmol 2001; 21: 37-8.
136. Evans RW, Rolak IA. Migraine versus multiple sclerosis. Headache 2001; 41: 97-8.
137. Fryze W, Zaborski J, Clonkowska A. Pain in the course of multiple sclerosis. Neurol Neurochir Pol 2002; 36: 275-84.
138. Pache M, Kaiser HJ, Akhalbedashvili N, Lienert C, Dubler B, Kappos L, Flammer J. Extraocular blood flow and endothelin-I plasma levels in patients with multiple sclerosis. Eur Neurol 2003; 49: 164-8.
139. Pagès N, Gogly B, Godeau G, Igondjo-Tchen S, Maurois P, Durlach J, Bac P. Structural alterations of the vascular wall in Mg-deficient mice. A possible role of gelatinase A (MMP2) and B (MMP9). Magnes Res 2003; 16: 43-8.
140. Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, Tommasi MA, Locatelli L, Cazzato G. Risk factors of multiple sclerosis: a case control study. Neurol Sci 2003; 24: 242-7.
141. Polacek L, Stein J. Experiences with sleep therapy of multiple sclerosis. Cesk Neurol 1959; 22: 20-9.
142. Mix E, Jensen HL, Lehmitz R, Lakner K, Hitzschke B, Richter M, Heydenreich A. Effect of pulsating electromagnetic field therapy on cell volume and phagocytosis activity in multiple sclerosis. Psychiatr Neurol Med Psychol (Leipzig) 1990; 42: 457-66.
143. Sandyk R. Electromagnetic fields for treatment of multiple sclerosis. Intern J Neuroscience 1996; 87: 1-4.
144. Sandyk R. Therapeutic effects of alternating current pulsed electromagnetic fields in multiple sclerosis. J Altern Complem Med 1997; 3: 365-86.
145. Richards TL, Lappin MS, Lawrie FW, Stegrauer KC. Bioelectromagnetic applications for multiple sclerosis. Phys Med Rehabil Clin N Am 1998; 9: 659-74.
146. Brola W, Wegrzyn W, Czernicki J. Effect of variable magnetic field on motor impairment and quality of life in patients with multiple sclerosis. Wiad Lek 2002; 55: 136-43.
147. Lappin MS, Lawrie FW, Richards TL, Kramer ED. Effects of a pulsed electromagnetic therapy on multiple sclerosis. Fatigue and quality of life: a double blind, placebo controlled trial. Altern Ther 2003; 9: 38-48.
148. Hedlmaier G, Hoffmann K. Melatonin stimulates growth of brown adipose tissue. Nature 1974; 247: 224-5.
149. Lawson K, Daum C. Turkewitz. Environmental characteristics of a neonatal intensive-care unit. Child Dev 1977; 48: 1633-9.
150. Mann NP, Haddow R, Strokes L, Rutter N. Effect of night and day on preterm infants in a newborn nurserey: randomized trial. BMJ 1986; 293: 1265-7.
151. Auliciems A, Barnes A. Sudden Infant deaths and clear weather in a subtropical environment. Soc Sci Med 1987; 24: 51-6.
152. Nelson EAS, Taylor BJ. Climatic and social association with post-neonatal mortality rates in New Zeland. New Zeland Med J 1988; 101: 443-6.
153. Blacburn S, Patteson D. Effects of cycled light on activity state and cardiorespiratory function in preterm infants. J Perinat Neonatal Nurs 1991; 4: 47-54.
154. Goldberg P, Fleming MC, Picard EH. Decreased relapse rate through dietary supplementation with Ca, Mg and vitamin D. Med Hypotheses 1986; 21: 193-200.
155. Durlach J, Durlach V, Bac P, Bara M, Guiet-Bara A. Magnesium and therapeutics. Magnes Res 1994; 7: 313-28.
156. Hyypa MT, Jolma T, Riekkinen P, Rinne UK. Effects of L-Tryptophan treatment on central indoleamine metabolism and short lasting-neurologic disturbances in multiple sclerosis. J Neural Transm 1975; 37: 297-304.
157. Scott Jr. CF, Cashman N, Spitler LE. Experimental allergic encephalitis: treatment with drugs which alter CNS serotonin levels. J Immunopharmacol 1982-1983; 4: 153-62.
158. Heiman-Patterson TD, Bird SJ, Parry GJ, Varga J, Shy ME, Culligan NW, Edelsohn L, Tatarian GT, Heyes MP, Garcia CA. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol 1990; 28: 522-8.
159. Arnouts PJ, Colemont LJ, Van Outryve MJ, Van Moer EM. L-Tryptophan-induced eosinophilia-myalgia syndrome. J Intern Med 1991; 230: 83-6.
160. Mayeno AN, Gleich GJ. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale. Trends Biotechnol 1994; 12: 346-52.
161. Sternberg EM. Pathogenesis of L-tryptophan eosinophilia-myalgia syndrome. Adv Exp Med Biol 1996; 398: 325-30.
162. Sandyk R. Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. Int J Neurosci 1996; 86: 47-53.
163. Gross B, Ronen N, Honigman S, Livne E. Tryptophan toxicity: time and dose response in rats. Adv Exp Med Biol 1999; 467: 507-16.
164. Lopez-Colome A, Erlig D, Pasantes-Morales H. Different effects of Ca flux blocking agents on light and K stimulated release of taurine from retina. Brain Res 1976; 113: 527-34.
165. Pasantes-Morales H, Ademe RM, Quesada U. Protective effects of taurine on the light induced disruption of isolated frog rot outer segments. J Neurosci Res 1981; 6: 337-48.
166. Sturman JA, Lu P, Xu YX, Imaki H. Feline maternal taurine deficiency: effects on visual cortex of the offspring. A moephometric and immunohistochemical study. In: Huxtable R, Michalk DV, eds. Taurine in Health and Disease. New-York: Plenum Publ., 1994: 369-92; Adv In Exp Med Biol; 359.
167. Sturman JA, Lu P, Xu YX, Imaki H. Feline maternal taurine deficiency: effects on visual cortex of the offspring. A moephometric and immunohistochemical study. In: Huxtable R, Michalk DV, eds. Taurine in Health and Disease. New-York: Plenum Publ., 1994: 369-92; Adv In Exp Med Biol; 359.
168. Stover JF, Pleines VE, Morganti-Kossman MC, Kossman T, Lowitzch K, Kempski OS. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997; 27: 1038-43.
169. Pasantes-Morales H, Quesada O, Moran J. Taurine: an osmolyte in mammalian tissue. In: Schaffer S, Lombardini JB, Huxtable RJ, eds. Taurine 3. New-York: Plenum publ., 1998: 209-17; Adv In Exp Med Biol; 442.
170. Pasantes-Morales H, Quesada O, Moran J. Taurine: an osmolyte in mammalian tissue. In: Schaffer S, Lombardini JB, Huxtable RJ, eds. Taurine 3. New-York: Plenum publ., 1998: 209-17; Adv In Exp Med Biol; 442.
171. Labiner DM, Yan CC, Weinand ME, Huxtable RJ. Disturbances of aminoacids from temporal lobe synaptosomes in human complex partial epilepsy. Neurochern Res 1999; 24: 1379-83.
172. Husy N, Deleuze C, Bres V, Moos FC. New role of taurine as an osmomediator between glial cells and neurons in the rat supraoptic nucleus. In: Della Corte L, Huxtable RJ, Sgaragli G, Tipton KF, eds. Taurine 4. New-York: Kluwer Ac, Plenum Publ., 2000: 227-37; Adv In Exp Med Biol; 483.
173. Husy N, Deleuze C, Bres V, Moos FC. New role of taurine as an osmomediator between glial cells and neurons in the rat supraoptic nucleus. In: Della Corte L, Huxtable RJ, Sgaragli G, Tipton KF, eds. Taurine 4. New-York: Kluwer Ac, Plenum Publ., 2000: 227-37; Adv In Exp Med Biol; 483.
174. Garseth M, White LR, Aasly J. Little change in CSF ami noacids in subtypes of multiple sclerosis compared with acute polyradiculoneuropathy. Neurochem Int 2001; 39: 111-5.